Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AK117 + Ivonescimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AK117 | AK 117|AK-117|Ligufalimab | CD47 Antibody 31 | AK117 is a monoclonal antibody that binds CD47, potentially resulting in decreased tumor growth (Journal for ImmunoTherapy of Cancer 2020;8). | |
Ivonescimab | AK112|AK 112|AK-112|SMT112|SMT 112|SMT-112 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 124 VEGFA Antibody 5 | Ivonescimab is a bispecific antibody that binds PD-1 and VEGFA, potentially resulting in antitumor activity (PMID: 37593227). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05382442 | Phase II | Ivonescimab Fluorouracil + Ivonescimab + Leucovorin + Oxaliplatin AK117 + Fluorouracil + Irinotecan + Ivonescimab + Leucovorin + Oxaliplatin AK117 + Fluorouracil + Ivonescimab + Leucovorin AK117 + Capecitabine + Ivonescimab + Oxaliplatin AK117 + Capecitabine + Ivonescimab Fluorouracil + Ivonescimab + Leucovorin AK117 + Ivonescimab Capecitabine + Ivonescimab + Oxaliplatin Fluorouracil + Irinotecan + Ivonescimab + Leucovorin + Oxaliplatin | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Recruiting | USA | 1 |